Mark Pines
Overview
Explore the profile of Mark Pines including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mordechay S, Smullen S, Evans P, Genin O, Pines M, Halevy O
Int J Mol Sci
. 2021 Jul;
22(13).
PMID: 34209117
Progressive loss of muscle and muscle function is associated with significant fibrosis in Duchenne muscular dystrophy (DMD) patients. Halofuginone, an analog of febrifugine, prevents fibrosis in various animal models, including...
2.
Barzilai-Tutsch H, Genin O, Pines M, Halevy O
Neuromuscul Disord
. 2020 May;
30(6):472-482.
PMID: 32451154
Dysferlinopathies are a non-lethal group of late-onset muscular dystrophies. Here, we evaluated the fusion ability of primary myoblasts from young dysf mice and the muscle histopathology prior to, and during...
3.
Wellner G, Mordechay S, Evans P, Genin O, Pines M, Halevy O
Histol Histopathol
. 2019 Jan;
34(7):791-801.
PMID: 30628720
In Duchenne muscular dystrophy (DMD), the progressive loss of muscle and its ability to function is associated with significant fibrosis, representing the major disease complication in patients. Halofuginone, a halogenated...
4.
Barzilai-Tutsch H, Dewulf M, Lamaze C, Butler Browne G, Pines M, Halevy O
Hum Mol Genet
. 2018 May;
27(16):2817-2829.
PMID: 29771357
In the absence of dysferlin, skeletal muscle cells fail to reseal properly after injury, resulting in slow progress of the dysferlinopathy muscular dystrophy (MD). Halofuginone, a leading agent in preventing...
5.
Pines M, Levi O, Genin O, Lavy A, Angelini C, Allamand V, et al.
Am J Pathol
. 2017 Jan;
187(3):654-664.
PMID: 28082118
Fibrosis is the main complication of muscular dystrophies. We identified moesin, a member of the ezrin-radixin-moesin family, in dystrophic muscles of mice representing Duchenne and congenital muscular dystrophies (DMD and...
6.
Barzilai-Tutsch H, Bodanovsky A, Maimon H, Pines M, Halevy O
Biochim Biophys Acta
. 2015 Oct;
1862(1):1-11.
PMID: 26454207
Halofuginone is a leading agent in preventing fibrosis and inflammation in various muscular dystrophies. We hypothesized that in addition to these actions, halofuginone directly promotes the cell-cycle events of satellite...
7.
Mayzlish-Gati E, Laufer D, Grivas C, Shaknof J, Sananes A, Bier A, et al.
Cancer Biol Ther
. 2015 Jul;
16(11):1682-8.
PMID: 26192476
Strigolactones (SLs) are a novel class of plant hormones. Previously, we found that analogs of SLs induce growth arrest and apoptosis in breast cancer cell lines. These compounds also inhibited...
8.
Anavi S, Eisenberg-Bord M, Hahn-Obercyger M, Genin O, Pines M, Tirosh O
Lab Invest
. 2015 Jun;
95(8):914-24.
PMID: 26097999
Accumulation of cholesterol in the liver is associated with the development of non-alcoholic steatohepatitis-related fibrosis. However, underlying mechanisms are not well understood. The present study investigated the role of inducible...
9.
Levi O, Genin O, Angelini C, Halevy O, Pines M
Oncotarget
. 2015 May;
6(27):23249-60.
PMID: 26015394
Duchenne Muscular Dystrophy is characterized by: near absence of dystrophin in skeletal muscles; low percentage of revertant myofibers; up-regulation of utrophin synthesis; and a high degree of muscle fibrosis. In...
10.
Pines M, Spector I
Molecules
. 2015 Jan;
20(1):573-94.
PMID: 25569515
Halofuginone is an analog of febrifugine-an alkaloid originally isolated from the plant Dichroa febrifuga. During recent years, halofuginone has attracted much attention because of its wide range of beneficial biological...